Relapsing Forms of Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing Forms of Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) [Phase 2]
A Phase 2 clinical trial evaluated the safety of BIIB091 and its effect on brain inflammation when taken alone or with diroximel fumarate in…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) [Phase 3]
Phase 3 trial of diroximel fumarate in adults with relapsing forms of multiple sclerosis in the Asia-Pacific region has completed, with resu…
-
FDA approval · 2025-08-18FDA Approved: OCREVUS ZUNOVO — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) from Genentech, expanding administration options …
-
FDA approval · 2024-06-10FDA Approved: AUBAGIO — Supplemental Application (Genzyme Corporation)
FDA approved Genzyme Corporation's supplemental application for AUBAGIO (teriflunomide).
-
FDA approval · 2024-06-05FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Mayzent (siponimod) submitted by Novartis Pharmaceuticals Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-06-05FDA Approved: ZEPOSIA 7-DAY STARTER PACK — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application to authorize a Zeposia 7-day starter pack (ozanimod hydrochloride) from Celgene Corporation.
-
FDA approval · 2023-08-18FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc. The action expands the drug's approved indication…
-
FDA approval · 2022-06-21FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA granted approval of a supplemental application for MAYZENT (siponimod) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2021-12-15FDA Approved: ZEPOSIA 7-DAY STARTER PACK — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application to introduce a 7-day starter pack of Zeposia (ozanimod hydrochloride) for Celgene Corporation.
-
FDA approval · 2021-05-27FDA Approved: ZEPOSIA 7-DAY STARTER PACK — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application to add a 7-day starter pack for ZEPOSIA (ozanimod hydrochloride), expanding dosing packaging for the…
-
FDA approval · 2020-04-28FDA Approved: BAFIERTAM — Original Application (Banner Life Sciences LLC)
FDA approved BAFIERTAM (monomethyl fumarate) from Banner Life Sciences LLC via an original NDA (NDA210296) for relapsing forms of multiple s…
-
CLINICAL_TRIALS trial_result · 2019-11-07Clinical Trial Update: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis [Phase 3]
Phase 3 trial update on long-term safety and tolerability of 0.5 mg fingolimod in relapsing forms of multiple sclerosis.
-
FDA approval · 2019-03-26FDA Approved: MAYZENT — Original Application (Novartis Pharmaceuticals Corporation)
FDA approves Mayzent (siponimod) from Novartis Pharmaceuticals Corporation in an original NDA for the treatment of relapsing forms of multip…
-
CLINICAL_TRIALS trial_result · 2016-07-25Clinical Trial Update: Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
The trial update reports the effectiveness of dimethyl fumarate and its impact on patient-reported outcomes in suboptimal glatiramer acetate…
-
CLINICAL_TRIALS withdrawal · 2016-04-13Clinical Trial Update: Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]
A Phase 3 placebo-controlled study of BG00012 (dimethyl fumarate) in pediatric relapsing-remitting multiple sclerosis has been withdrawn.
-
FDA label_change · 2016-01-19FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation. The action updates the drug's l…
-
CLINICAL_TRIALS trial_result · 2014-11-11Clinical Trial Update: Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States [Phase 4]
Phase 4 trial evaluating the gastrointestinal tolerability of dimethyl fumarate in adults with relapsing forms of multiple sclerosis; result…